Anapen® Prescriber Checklist

adrenaline (epinephrine)

Patient's Name:.....

The purpose of this checklist is to help you advise your patient on the correct use and storage of Anapen® adrenaline auto-injectors. Please ensure you have answered "**YES**" to all the questions on the list before prescribing or renewing the medication.

		YES	NO
1.	Have you read the Summary of Product Characteristics (SmPC) and checked the criteria in relation to Contraindications and Special Warnings and Precautions for Use available at www.anapen.ie?		
2.	Have you prescribed two adrenaline auto-injectors?		
3.	Have you informed the patient that he/she should carry 2 adrenaline auto-injectors at all times in case symptoms do not improve and a second dose is needed?		
4.	Have you explained to the patient when adrenaline should be self-administered?		
5.	Have you explained the exact steps to follow when self-injecting adrenaline using the available training device?		
6.	Have you provided the patient with a training device (with no needle or medication) to practice administration in an emergency situation?		
7.	Have you advised the patient to call emergency services at 999 or 112 saying "anaphylaxis" as soon as he/she has injected the adrenaline, even if symptoms are improving?		
8.	Have you informed the patient that if their symptoms have not improved or have gotten worse in the 5 to 15 minutes after the first injection, a second injection should be used?		
9.	Have you instructed the patient not to store the training device and the Anapen® device containing medication in the same place?		
10.	Has the patient been instructed to store their Anapen® device below 25ºC in the outer carton to protect it from light and to avoid freezing the product?		
11.	Have you recommended that the patient watch the demonstration video available at YouTube www.tiny.cc/anapen		
12.	Has the patient been advised to regularly check their Anapen® device and ensure it is replaced within the expiry date or if the solution is discoloured or contains a precipitate?		
13.	Have you instructed the patient or their carer to fully read the Patient Information Leaflet to become familiar with it?		

Date:..... Prescriber's Signature: .....

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse reactions should also be reported to Bioprojet on Tel: 01 686 9342 or pharmacovigilance@bioprojet.com

bioprojet

Code ANA/IE/17/22 | November 2022